Diagnostics considerations in juvenile parkinsonism

Movement Disorders

Volumn 19, Issue 2, 2004, Pages 123-135

  Paviour, Dominic C ^a   Surtees, Robert A H ^b   Lees, Andrew J ^a,c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Juvenile parkinsonism; Parkin

Indexed keywords

6 FLUORODOPA; AMLODIPINE; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CHLOROQUINE; CINNARIZINE; DIMERCAPROL; DOPAMINE; DOXORUBICIN; FLUNARIZINE; IODINE 123; LEVODOPA; MEASLES VACCINE; METOCLOPRAMIDE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROLEPTIC AGENT; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PARKIN; PENICILLAMINE; PHENYLALANINE; PROCHLORPERAZINE; TETRAHYDROBIOPTERIN; TETRATHIOMOLYBDIC ACID; TRIENTINE; TYROSINE 3 MONOOXYGENASE; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; ZINC; UBIQUITIN PROTEIN LIGASE;

ACANTHOCYTOSIS; ADOLESCENT; ADOLESCENT DISEASE; AKATHISIA; AUTOSOMAL RECESSIVE DISORDER; BASAL GANGLION; BONE MARROW TRANSPLANTATION; BRADYKINESIA; BRAIN INJURY; CELL NUCLEUS INCLUSION BODY; CENTRAL PONTINE MYELINOLYSIS; CLINICAL FEATURE; DIAGNOSTIC TEST; DIFFUSE LEWY BODY DISEASE; DRUG INDUCED DISEASE; DRUG RESPONSE; DYSTONIA; EPIDEMIC ENCEPHALITIS; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; HYPOTENSION; HYPOXIA; IDIOPATHIC DISEASE; INTOXICATION; LUNG ASPERGILLOSIS; METABOLIC DISORDER; MITOCHONDRION; MYCOPLASMA PNEUMONIA; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINOCEREBELLAR DEGENERATION; SUBACUTE SCLEROSING PANENCEPHALITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; WILSON DISEASE; ADULT; BRAIN; CHROMOSOME ABERRATION; GENETICS; LEWY BODY; MUTATION; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PATHOLOGY; RECESSIVE GENE;

ADOLESCENT; ADULT; BRAIN; CHROMOSOME ABERRATIONS; GENES, RECESSIVE; HUMANS; LEWY BODIES; MUTATION; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PARKINSONIAN DISORDERS; UBIQUITIN-PROTEIN LIGASES;

EID: 1542300954     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10644     Document Type: Review

References (132)

1. de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-15.
2. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
3. Ludecke B, Knappskog PM, Clayton PT, et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996;5:1023-1028.
4. Ramsay Hunt J. Progressive atrophy of the globus pallidus. Brain 1917;40:923-975.
5. Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 1988;38:1402-1406.
6. Mizutani Y, Yokochi M, Oyanagi S. Juvenile parkinsonism: a case with first clinical manifestation at the age of six years and with neuropathological findings suggesting a new pathogenesis. Clin Neuropathol 1991;10:91-97.
7. Pranzatelli MR, Mott SH, Pavlakis SG, Conry JA, Tate ED. Clinical spectrum of secondary parkinsonism in childhood: a reversible disorder. Pediatr Neurol 1994;10:131-140.
8. Schrag A, Ben Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited - clinical features, natural history, and mortality. Mov Disord 1998;13:885-894.
9. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
10. Lucking CB, Durr A, Bonifati V, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 2000;342:1560-1567.
11. Jeon BS, Kim JM, Lee DS, Hattori N, Mizuno Y. An apparently sporadic case with parkin gene mutation in a Korean woman. Arch Neurol 2001;58:988-989.
12. Hattori N, Kitada T, Matsumine H, et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol 1998;44:935-941.
13. Golbe LI, Di Iorio G, Sanges G, et al. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol 1996;40: 767-775.
14. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-259.
15. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002;51:296-301.
16. Hicks AA, Petursson H, Jonsson T, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002;52: 549-555.
17. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392:605-608.
18. Portman AT, Giladi N, Leenders KL, et al. The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations. Neurology 2001;56:1759-1762.
19. Leenders KL, Salmon EP, Tyrrell P, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
20. Thobois S, Ribeiro MJ, Lohmann E, et al. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study. Arch Neurol 2003;60:713-718.
21. Khan NL, Brooks DJ, Pavese N, et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002;125:2248-2256.
22. van de Warrenburg BP, Lammens M, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001;56:555-557.
23. Khan NL, Graham E, Critchley P, et al. Parkin disease: a phenotypic study of a large case series. Brain 2003;126:1279-1292.
24. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001;50:293-300.
25. Hayashi S, Wakabayashi K, Ishikawa A, et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 2000;15: 884-888.
26. Mori H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998;51:890-892.
27. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991;41: 174-181.
28. Nygaard TG. Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis. Adv Neurol 1993;60:577-585.
29. Swaans RJ, Rondot P, Renier WO, Van Den Heuvel LP, Steenbergen-Spanjers GC, Wevers RA. Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism. Ann Hum Genet 2000;64:25-31.
30. de Rijk-Van Andel JF, Gabreels FJ, et al. L-dopa-responsive infantile hypokinetic rigid parkinsonism due to tyrosine hydroxylase deficiency. Neurology 2000;55:1926-1928.
31. Grattan-Smith PJ, Wevers RA, Steenbergen-Spanjers GC, Fung VS, Earl J, Wilcken B. Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy. Mov Disord 2002;17:354-359.
32. Tassin J, Durr A, Bonnet AM, et al. Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain 2000;123: 1112-1121.
33. O'Sullivan JD, Costa DC, Gacinovic S, Lees AJ. SPECT imaging of the dopamine transporter in juvenile-onset dystonia. Neurology 2001;56:266-267.
34. 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia. Neurology 1993;43:1563-1568.
35. Hyland K, Fryburg JS, Wilson WG, et al. Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test. Neurology 1997;48:1290-1297.
36. Bandmann O, Goertz M, Zschocke J, et al. The phenylalanine loading test in the differential diagnosis of dystonia. Neurology 2003;60:700.
37. Walshe JM, Yealland M. Wilson's disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 1992;55:692-696.
38. Orth M, Schapira AH. Mitochondria and degenerative disorders. Am J Med Genet 2001;106:27-36.
39. Walshe JM, Yealland M. Not Wilson's disease: a review of mis-diagnosed cases. QJM 1995;88:55-59.
40. Negrotti A, Calzetti S. A long-term follow-up study of cinnarizine-and flunarizine-induced parkinsonism. Mov Disord 1997;12:107-110.
41. Teive HA, Germiniani FM, Werneck LC. Parkinsonian syndrome induced by amlodipine: case report. Mov Disord 2002;17:833-835.
42. Padrell MD, Navarro M, Faura CC, Horga JF. Verapamil-induced parkinsonism. Am J Med 1995;99:436.
43. Parmar RC, Valvi CV, Kamat JR, Vaswani RK. Chloroquine induced parkinsonism. J Postgrad Med 2000;46:29-30.
44. Boranic M, Raci F. A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia. Biomedicine 1979;31:124-125.
45. Alvarez-Gomez MJ, Vaamonde J, Narbona J, et al. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol 1993;16:451-455.
46. Misra UK, Kalita J. Prognosis of Japanese encephalitis patients with dystonia compared to those with parkinsonian features only. Postgrad Med J 2002;78:238-241.
47. Hsieh JC, Lue KH, Lee YL. Parkinson-like syndrome as the major presenting symptom of Epstein-Barr virus encephalitis. Arch Dis Child 2002;87:358.
48. Garg RK. Subacute sclerosing panencephalitis. Postgrad Med J 2002;78:63-70.
49. Sawaishi Y, Yano T, Watanabe Y, Takada G. Migratory basal ganglia lesions in subacute sclerosing panencephalitis (SSPE): clinical implications of axonal spread. J Neurol Sci 1999;168:137-140.
50. Hersh BP, Rajendran PR, Battinelli D. Parkinsonism as the presenting manifestation of HIV infection: improvement on HAART. Neurology 2001;56:278-279.
51. Bennett BA, Rusyniak DE, Hollingsworth CK. HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. Brain Res 1995;705:168-176.
52. Singer C, Berger JR, Bowen BC, Bruce JH, Weiner WJ. Akinetic-rigid syndrome in a 13-year-old girl with HIV-related progressive multifocal leukoencephalopathy. Mov Disord 1993;8:113-116.
53. de Mattos JP, Rosso AL, Correa RB, Novis SA. Movement disorders in 28 HIV-infected patients. Arq Neuropsiquiatr 2002;60: 525-530.
54. Kelly DV, Beique LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 2002; 36:827-830.
55. Howard RS, Lees AJ. Encephalitis lethargica. A report of four recent cases. Brain 1987;110:19-33.
56. Dale RC, Church AJ, Surtees RA, Lees AJ, Neville BG, Giovannoni G. Re-emergence of encephalitis lethargica: new evidence of an autoimmune disease. J Neurol Neurosurg Psychiatry 2002;73: 213-236.
57. Alves RS, Barbosa ER, Scaff M. Postvaccinal parkinsonism. Mov Disord 1992;7:178-180.
58. Kim JS, Choi IS, Lee MC. Reversible parkinsonism and dystonia following probable mycoplasma pneumoniae infection. Mov Disord 1995;10:510-512.
59. Smith R, Eviatar L. Neurologic manifestations of Mycoplasma pneumoniae infections: diverse spectrum of diseases. A report of six cases and review of the literature. Clin Pediatr (Phila) 2000; 39:195-201.
60. Bottas A, Richter MA. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). Pediatr Infect Dis J 2002;21:67-71.
61. Dale RC, Church AJ, Surtees RA, Thompson EJ, Giovannoni G, Neville BG. Post-streptococcal autoimmune neuropsychiatric disease presenting as paroxysmal dystonic choreoathetosis. Mov Disord 2002;17:817-820.
62. Squitieri F, Berardelli A, Nargi E, et al. Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis. Clin Genet 2000;58:50-56.
63. Young AB, Shoulson I, Penney JB, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 1986;36:244-249.
64. Gwinn-Hardy K, Singleton A, O'Suilleabhain P, et al. Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. Arch Neurol 2001;58:296-299.
65. Gwinn-Hardy K, Chen JY, Liu HC, et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 2000;55: 800-805.
66. Lee WY, Jin DK, Oh MR, et al. Frequency analysis and clinical characterization of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Korean patients. Arch Neurol 2003;60:858.
67. Schols L, Peters S, Szymanski S, et al. Extrapyramidal motor signs in degenerative ataxias. Arch Neurol 2000;57:1495-1500.
68. Subramony SH, Hernandez D, Adam A, et al. Ethnic differences in the expression of neurodegenerative disease: Machado-Joseph disease in Africans and Caucasians. Mov Disord 2002;17: 1068-1071.
69. Sasaki H, Wakisaka A, Sanpei K, et al. Phenotype variation correlates with CAG repeat length in SCA2 - a study of 28 Japanese patients. J Neurol Sci 1998;159:202-208.
70. Schols L, Gispert S, Vorgerd M, et al. Spinocerebellar ataxia type 2. Genotype and phenotype in German kindreds. Arch Neurol 1997;54:1073-1080.
71. Haydeh Payami, John Nutt, Steven Gancher, et al. SCA2 may present as levodopa-responsive parkinsonism. Mov Disord 2003; 18:425-429.
72. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991;114:13-49.
73. Peppard RF, Lu CS, Chu NS, Teal P, Martin WR, Calne DB. Parkinsonism with neuroacanthocytosis. Can J Neurol Sci 1990; 17:298-301.
74. Dobson-Stone C, Danek A, Rampoldi L, et al. Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet 2002;10:773-781.
75. Pittock SJ, Joyce C, O'Keane V, et al. Rapid-onset dystonia-parkinsonism: a clinical and genetic analysis of a new kindred. Neurology 2000;55:991-995.
76. Kramer PL, Mineta M, Klein C, et al. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13. Ann Neurol 1999;46:176-182.
77. De Coo IF, Renier WO, Ruitenbeek W, et al. A 4-base pair deletion in the mitochondrial cytochrome b gene associated with parkinsonism/MELAS overlap syndrome. Ann Neurol 1999;45:130-133.
78. Straussberg R, Shahar E, Gat R, Brand N. Delayed parkinsonism associated with hypotension in a child undergoing open-heart surgery. Dev Med Child Neurol 1993;35:1011-1014.
79. Edby K, Larsson J, Eek M, von Wendt L, Ostergard B. Amantadine treatment of a patient with anoxic brain injury. Childs Nerv Syst 1995;11:607-609.
80. Mott SH, Packer RJ, Vezina LG, et al. Encephalopathy with parkinsonian features in children following bone marrow transplantations and high-dose amphotericin B. Ann Neurol 1995;37: 810-814.
81. Pirker W, Baumgartner C, Brugger S, et al. Severe akinetic syndrome resulting from a bilateral basal ganglia lesion following bone marrow transplantation. Mov Disord 1999;14:525-528.
82. Curran T, Lang AE. Parkinsonian syndromes associated with hydrocephalus: case reports, a review of the literature, and pathophysiological hypotheses. Mov Disord 1994;9:508-520.
83. Krauss JK, Nobbe F, Wakhloo AK, Mohadjer M, Vach W, Mundinger F. Movement disorders in astrocytomas of the basal ganglia and the thalamus. J Neurol Neurosurg Psychiatry 1992;55:1162-1167.
84. Pohle T, Krauss JK. Parkinsonism in children resulting from mesencephalic tumors. Mov Disord 1999;14:842-846.
85. Skiming JA, McDowell HP, Wright N, May P. Secondary parkinsonism: an unusual late complication of craniospinal radiotherapy given to a 16-month child. Med Pediatr Oncol 2003; 40:132-134.
86. Nagamitsu S, Matsuishi T, Yamashita Y, Yamada S, Kato H. Extrapontine myelinolysis with parkinsonism after rapid correction of hyponatremia: high cerebrospinal fluid level of homovanillic acid and successful dopaminergic treatment. J Neural Transm 1999;106:949-953.
87. Lindenberg R, Rubinstein LJ, Herman MM, Haydon GB. A light and electron microscopy study of an unusual widespread nuclear inclusion body disease. A possible residuum of an old herpesvirus infection. Acta Neuropathol (Berl) 1968;10:54-73.
88. Kimber TE, Blumbergs PC, Rice JP, Hallpike JF, Edis R, Thompson PD, Suthers G. Familial neuronal intranuclear inclusion disease with ubiquitin positive inclusions. J Neurol Sci 1998;160:33-40.
89. O'Sullivan JD, Hanagasi HA, Daniel SE, Tidswell P, Davies SW, Lees AJ. Neuronal intranuclear inclusion disease and juvenile parkinsonism. Mov Disord 2000;15:990-995.
90. Kish SJ, Gilbert JJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O. Brain neurotransmitter abnormalities in neuronal intranuclear inclusion body disorder. Ann Neurol 1985;17:405-407.
91. Funata N, Maeda Y, Koike M, et al. Neuronal intranuclear hyaline inclusion disease: report of a case and review of the literature. Clin Neuropathol 1990;9:89-96.
92. Waggener JD, Beggs J, Sidell AD. Virus like filaments in juvenile parkinsonism. J Neuropathol Exp Neurol 1978;31:187.
93. Greco CM, Hagerman RJ, Tassone F, et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002;125:1760-1771.
94. Munoz E, Rey MJ, Mila M, et al. Intranuclear inclusions, neuronal loss and CAG mosaicism in two patients with Machado-Joseph disease. Journal of the Neurological Sciences 2002;200:19-25.
95. Walker RH, Morgello S, Davidoff-Feldman B, et al. Autosomal dominant chorea-acanthocytosis with polyglutamine-containing neuronal inclusions. Neurology 2002;58:1031-1037.
96. Takahashi J, Fukuda T, Tanaka J, Minamitani M, Fujigasaki H, Uchihara T. Neuronal intranuclear hyaline inclusion disease with polyglutamine-immunoreactive inclusions. Acta Neuropathol (Berl) 2000;99:589-594.
97. Carstea ED, Morris JA, Coleman KG, et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science 1997;277:228-231.
98. Coleman RJ, Robb SA, Lake BD, Brett EM, Harding AE. The diverse neurological features of Niemann-Pick disease type C: a report of two cases. Mov Disord 1988;3:295-299.
99. Gardiner M, Sandford A, Deadman M, et al. Batten disease (Spielmeyer-Vogt disease, juvenile onset neuronal ceroid-lipofuscinosis) gene (CLN3) maps to human chromosome 16. Genomics 1990;8:387-390.
100. Jarvela I, Autti T, Lamminranta S, Aberg L, Raininko R, Santavuori P. Clinical and magnetic resonance imaging findings in Batten disease: analysis of the major mutation (1.02-kb deletion). Ann Neurol 1997;42:799-802.
101. Aberg LE, Rinne JO, Rajantie I, Santavuori P. A favorable response to antiparkinsonian treatment in juvenile neuronal ceroid lipofuscinosis. Neurology 2001;56:1236-1239.
102. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 2001;28:345-349.
103. Galvin JE, Giasson B, Hurtig HI, Lee VMY, Trojanowski JQ. Neurodegeneration with brain iron accumulation, type 1 is characterized by α-, β-, and γ-synuclein neuropathology. Am J Pathol 2000;157:361-368.
104. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003;348:33-40.
105. Higgins JJ, Patterson MC, Papadopoulos NM, Brady RO, Pentchev PG, Barton NW. Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome). Neurology 1992;42:194-198.
106. Kyllerman M, Brandberg G, Wiklund LM, Mansson JE. Dysarthria, progressive parkinsonian features and symmetric necrosis of putamen in a family with painful lipomas (Dercum disease variant). Neuropediatrics 2002;33:69-72.
107. Keskin S, Yurdakul F. Parkinsonian manifestations in a patient with homocystinuria. J Child Neurol 1996;11:235-236.
108. Clayton PT, Smith I, Harding B, Hyland K, Leonard JV, Leeming RJ. Subacute combined degeneration of the cord, dementia and parkinsonism due to an inborn error of folate metabolism. J Neurol Neurosurg Psychiatry 1986;49:920-927.
109. Choi IS. Parkinsonism after carbon monoxide poisoning. Eur Neurol 2002;48:30-33.
110. Shahar E, Andraws J. Extra-pyramidal parkinsonism complicating organophosphate insecticide poisoning. Eur J Paediatr Neurol 2001;5:261-264.
111. Uitti RJ, Rajput AH, Ashenhurst EM, Rozdilsky B. Cyanide-induced parkinsonism: a clinicopathologic report. Neurology 1985;35:921-925.
112. Davis LE, Adair JC. Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs. Mov Disord 1999;14:520-522.
113. Garcia-Moreno JM, Chacon J. Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: case report and review of the literature. Mov Disord 2002;17:1329-1335.
114. Derex L, Trouillas P. Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy. Mov Disord 1997;12:612-613.
115. Hirooka Y, Yuasa K, Hibi K, et al. Hyperparathyroidism associated with parkinsonism. Intern Med 1992;31:904-907.
116. Kovacs CS, Howse DC, Yendt ER. Reversible parkinsonism induced by hypercalcemia and primary hyperparathyroidism. Arch Intern Med 1993;153:1134-1136.
117. Pearson DW, Durward WF, Fogelman I, Boyle IT, Beastall G. Pseudohypoparathyroidism presenting as severe Parkinsonism. Postgrad Med J 1981;57:445-447.
118. Manyam BV, Walters AS, Keller IA, Ghobrial M. Parkinsonism associated with autosomal dominant bilateral striopallidodentate calcinosis. Parkinsonism Relat Disord 2001;7:289-295.
119. Uldry PA, Bogousslavsky J. Partially reversible parkinsonism in Whipple's disease with antibiotherapy. Eur Neurol 1992;32:151-153.
120. Golbe LI, Miller DC, Duvoisin RC. Paraneoplastic degeneration of the substantia nigra with dystonia and parkinsonism. Mov Disord 1989;4:147-152.
121. Pettit RE, Berdal KG. Chediak-Higashi syndrome. Neurologic appearance. Arch Neurol 1984;41:1001-1002.
122. Hauser RA, Friedlander J, Baker MJ, Thomas J, Zuckerman KS. Adult Chediak-Higashi parkinsonian syndrome with dystonia. Mov Disord 2000;15:705-708.
123. Grandas F, Martin-Moro M, Garcia-Munozguren S, Anaya F. Early-onset parkinsonism in cerebrotendinous xanthomatosis. Mov Disord 2002;17:1396-1397.
124. Gibb WR, Narabayashi H, Yokochi M, Iizuka R, Lees AJ. New pathologic observations in juvenile onset parkinsonism with dystonia. Neurology 1991;41:820-822.
125. Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH. Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease. Hum Genet 1998;103:424-427.
126. Tassin J, Durr A, de Broucker T, et al. Chromosome 6-linked autosomal recessive early-onset Parkinsonism: linkage in European and Algerian families, extension of the clinical spectrum, and evidence of a small homozygous deletion in one family. The French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Am J Hum Genet 1998;63:88-94.
127. Maruyama M, Ikeuchi T, Saito M, et al. Novel mutations, pseudodominant inheritance, and possible familial affects in patients with autosomal recessive juvenile parkinsonism. Ann Neurol 2000;48:245-250.
128. Klein C, Pramstaller PP, Kis B, et al. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 2000;48:65-71.
129. Nisipeanu P, Inzelberg R, Abo Mouch S, et al. Parkin gene causing benign autosomal recessive juvenile parkinsonism. Neurology 2001;56:1573-1575.
130. Hedrich K, Marder K, Harris J, et al. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology 2002;58:1239-1246.
131. West A, Periquet M, Lincoln S, et al. Complex relationship between Parkin mutations and Parkinson disease. Am J Med Genet 2002;114:584-591.
132. Hoenicka J, Vidal L, Morales B, et al. Molecular findings in familial Parkinson disease in Spain. Arch Neurol 2002;59:966-970.